Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

OBJECTIVE: To evaluate the efficacy, safety and dose response of a novel oral Janus kinase inhibitor, peficitinib (ASP015K), as monotherapy in Japanese patients with moderate to severe rheumatoid arthritis (RA). METHODS: In a 12-week, double-blind study, 281 adult patients with RA with active diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Iwasaki, Manabu, Ishikura, Hiroaki, Saeki, Satoshi, Kaneko, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893099/
https://www.ncbi.nlm.nih.gov/pubmed/26672064
http://dx.doi.org/10.1136/annrheumdis-2015-208279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893099/
https://www.ncbi.nlm.nih.gov/pubmed/26672064
http://dx.doi.org/10.1136/annrheumdis-2015-208279

Ejemplares similares